Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

BMO Capital Sees Almost 300% Upside On Centessa Stock

  • BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ:CNTA) with a price target of $19 (293% upside), and an Outperform rating.
  • The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD. Early ZF874 data (N=2) demonstrated therapeutic efficacy in patients, but liver toxicity was also flagged.
  • Centessa is currently trying to identify an optimal dose that circumvents the liver toxicity while maintaining efficacy. The data readout is expected in 2H22.
  • The analyst notes that the hemophilia program with potential FDA approval in 2026 could drive short-term upside.
  • SerpinPC is differentiated against most approved/investigational hemophilia treatments as it doesn’t trigger thrombosis and comes with convenient dosing. 
  • Read Next: Centessa Stock Surges On Positive Data From Hemophilia Candidate.
  • An open-label extension study readout is planned for 4Q22.
  • Price Action: CNTA shares are up 16.67% at $4.83 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.